Simulation Models for Comparison of Toxicities of Anticancer Drugs
This retrospectivestudy presents simulation models foranalyzing toxicities of doxorubicin and docetaxel, bothin combination of cyclophosphamide (AC and TC). Itcomparedtheir side effectsduring postoperative chemotherapy of the treated Pakistani breast tumor patients. Between September 2015 and September 2017, patients out of 356 received TC (600 mg/m2 of cyclophosphamide, 75 mg/m2 of docetaxel) and 168received AC (600 mg/m2of cyclophosphamide,60 mg/m2 of doxorubicin). Using simulation and modeling the study presents two simulation models called SMG1SE, (Simulation Model for Side Effects listed in Group 1) and SMG2SE (Simulation Model for Side Effects listed in Group 2). SMG1SE shows drugs toxicity based on side effects, listed in group 1 including muscles pain, mild anemia, moderate anemia, blood transfusion, weight loss, and hands burning. SMG2SE shows toxicity basedon side effects, listed in group 2 including vomiting, change in taste, sores in throat, diarrhea, tiredness, and dizziness.At α=0.05, chi-squared test was used for statistical analysis.It was observed no significant difference between the percentagesof patientswith extreme tiredness, stability, mild anemia,vomiting, and diarrhea forP-valueremained>0.05. Though, AC(P-value<0.05)was found less toxic by 25.7%, 22.6%, 25.3%,20.8%,16.4%, and 12.4% and compared to TC for muscle pain,changes in taste, burning hands,moderate anemia, needing blood transfusion, and change in hemoglobin level, respectively, but TC was found less toxic by 32.5%, 26.3%, and 52.9% for weight loss,sores in throat and mouth, and dizziness respectively.At 24 months, AC remainedless toxic than TC.